Amanda Brandner
Nurse Practitioner · Knoxville, TNNPI 1235817040
Payments from drug & device makers
Across 274 payments — averaging $16.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$682
- AstraZeneca$616
- Lilly USA, LLC$563
- Novo Nordisk$486
- Bayer$298
- Pfizer$282
- plus $2K from 19 others
What the payments were for
- Food & beverage$4,566100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 47 | $682 |
| AstraZeneca | 34 | $616 |
| Lilly USA, LLC | 30 | $563 |
| Novo Nordisk | 27 | $486 |
| Bayer | 20 | $298 |
| Pfizer | 21 | $282 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 14 | $243 |
| Boehringer Ingelheim | 10 | $170 |
| Dexcom, Inc. | 8 | $167 |
| GSK | 9 | $161 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $148 |
| Phathom Pharmaceuticals, Inc. | 9 | $141 |
| Amgen | 7 | $105 |
| Axsome Therapeutics, Inc. | 5 | $96 |
| Xeris Pharmaceuticals, Inc. | 6 | $91 |
| Novartis | 3 | $67 |
| Antares Pharma, Inc. | 3 | $51 |
| Astellas Pharma US Inc | 2 | $38 |
| Inspire Medical Systems, Inc. | 1 | $38 |
| Otsuka America Pharmaceutical, Inc. | 2 | $34 |
| Exact Sciences | 2 | $27 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Tolmar, Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
How this compares
$4,566 in reported general payments places this provider in the 90th percentile of 2,662 nurse practitioner providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 32 | $42,492 |
| MounjaroTirzepatide | 22 | $25,169 |
| EliquisApixaban | 30 | $18,886 |
| JanuviaSitagliptin Phosphate | 21 | $13,503 |
| MyrbetriqMirabegron | 14 | $8,734 |
| JardianceEmpagliflozin | 14 | $8,183 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $7,995 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $5,720 |
| Arnuity ElliptaFluticasone Furoate | 11 | $3,022 |
| SynthroidLevothyroxine Sodium | 33 | $2,150 |
| Levothyroxine Sodium | 203 | $1,415 |
| Olmesartan Medoxomil | 73 | $1,295 |
| LantusInsulin Glargine,hum.Rec.Anlog | 12 | $1,209 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 12 | $930 |
| Rosuvastatin Calcium | 71 | $905 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $486 | $42,49232 claims |
| Lilly USA, LLCMounjaro | $563 | $25,16922 claims |
| PfizerEliquis | $282 | $18,88630 claims |
| GSKAnoro Ellipta, Arnuity Ellipta | $161 | $8,74223 claims |
| Astellas Pharma US IncMyrbetriq | $38 | $8,73414 claims |
| Boehringer IngelheimJardiance | $170 | $8,18314 claims |
| AbbVieSynthroid | $682 | $2,15033 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,662 nurse practitioner providers in Tennessee.
Other nurse practitioner in Knoxville
- Karen RodenKnoxville$265K
- Erica HembreeKnoxville$125K
- Robin LovedayKnoxville$56K
- Tiffany SteelmanKnoxville$21K
- Jennifer BerryKnoxville$19K
- Erica HillKnoxville$13K
- Amy HatcherMurfreesboro$1.1M
- Susan UtleyNashville$194K
- Whitney EricksonMemphis$159K
- Brooke FaughtNashville$89K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.